Alexi Wright, MD
Enriched profileAssociate Professor of Medicine, Harvard Medical School; Director, Gynecologic Oncology Outcomes Research, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Alexi Wright is Associate Professor of Medicine, Harvard Medical School; Director, Gynecologic Oncology Outcomes Research, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 270 publications with 15,804 citations (h-index 56); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Alexi Wright, MD, is Associate Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute / Harvard Medical School. The public record shows 270 publications with 15,804 citations (h-index 56), centered on Cancer survivorship and care, Palliative Care and End-of-Life Issues, Ovarian cancer diagnosis and treatment. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 3 companies, 6 NIH-funded awards (2013–2026).
- Most recent indexed publication: 2026 · Neurology
- Top research focus: Cancer survivorship and care
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 25 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 107.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- BRIDGE-SIC Efficacy Trial
Sponsor: Dana-Farber Cancer Institute
- BOLSTER: Learning New Skills to Thrive
Sponsor: Dana-Farber Cancer Institute
- REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 18 Oct 2026
3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
- Merck Sharp & Dohme LLCProgram year20232 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.3%Kinase inhibitor53.3%Lenvima100%Part D<11 patientsBlood & clotting
46.7%Factor Xa inhibitor46.7%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
6 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:
- Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level Analysis
Dana-Farber Cancer Inst
FY2026$715,755R01CA279414 - Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors
Dana-Farber Cancer Inst
FY2026$677,174R01CA289547 - BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Cancer - a Multi-Site Randomized Controlled Trial
Dana-Farber Cancer Inst
FY2026$669,032R01CA270040
Congress activity
Updated 18 Oct 2026
70 congress contributions (2008–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).
ASCO Annual Meeting
ASCO2025Co-author - Early post-operative opioid fills after cancer-directed surgery among Medicare beneficiaries by race and ethnicity.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Cancer Screening, Diagnosis, and Treatment for Vulnerable Patients Incarcerated in US Prisons.
JCO oncology practice
Article2026 - When Is the Right Time? A Qualitative Study of Timing of Specialty Palliative Care in Patients With Brain Tumors.
JCO oncology practice
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Health Care Costs in the Last Week of Life901 citations2009
- 03Landscape of genomic alterations in cervical carcinomas884 citations2013
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/alexi-wright-md-1
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dana-farberbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dana-farberbrigham.org ↗
- MD
University of Pennsylvania School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - MPH
Harvard School of Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Internal Medicine Residency
Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Medical Oncology Fellowship
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Director
Gynecologic Oncology Outcomes Research, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Member
Cancer Care Delivery Research Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Member
Gynecologic Cancers Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Organizer
Dana-Farber/Harvard Cancer Center Outcomes Research Seminar
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providers.dana-farberbrigham.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eurekalert.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Frank Hodi, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute